Published in J Cell Mol Med on July 01, 2012
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene (2014) 0.94
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Cancer Biol Ther (2015) 0.83
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther (2015) 0.80
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. Int J Mol Sci (2016) 0.78
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget (2016) 0.78
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget (2016) 0.76
Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag (2014) 0.75
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. Int J Endocrinol (2015) 0.75
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology (2016) 0.75
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. Oncologist (2016) 0.75
Igf-I influences everolimus activity in medullary thyroid carcinoma. Front Endocrinol (Lausanne) (2015) 0.75
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines. Mol Oncol (2017) 0.75
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle (2008) 3.37
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Medullary thyroid carcinoma. Clin Endocrinol (Oxf) (2004) 1.42
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology (2007) 1.31
Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res (2010) 1.18
Cellular senescence in the development and treatment of cancer. Curr Pharm Des (2010) 1.17
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology (2007) 1.11
Senescence induction; a possible cancer therapy. Mol Cancer (2009) 1.10
Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) (2001) 1.06
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res (2006) 1.01
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer (2010) 1.00
Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer (2001) 0.97
Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab (2000) 0.93
The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol (2009) 0.89
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab (2006) 0.89
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol (2009) 0.88
Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol (2009) 0.88
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer (1996) 0.84
Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res (2004) 0.83
mTOR favors senescence over quiescence in p53-arrested cells. Aging (Albany NY) (2010) 0.81
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res (2002) 0.78
Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell (1995) 4.39
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett (1999) 3.00
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol (1999) 2.40
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Regional effects and mechanism of positive end-expiratory pressure in early adult respiratory distress syndrome. JAMA (1993) 2.21
Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) (2000) 2.19
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab (1997) 2.14
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Hydrogen peroxide-related colitis (previously known as "pseudolipomatosis"): a series of cases occurring in an epidemic pattern. Endoscopy (2007) 2.07
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int (2013) 2.00
Psoas compartment block for anaesthesia during surgical repair of inguinal hernias. Br J Anaesth (2013) 1.99
Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet (1999) 1.98
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol (2014) 1.97
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer (2006) 1.84
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol (2004) 1.79
Mediators of lifestyle behavior change in Native Hawaiians: initial findings from the Native Hawaiian Diabetes Intervention Program. Diabetes Care (2001) 1.75
Comparison of two methods for weaning patients with chronic obstructive pulmonary disease requiring mechanical ventilation for more than 15 days. Am J Respir Crit Care Med (2001) 1.75
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Attempted limb lengthenings beyond twenty percent of the initial bone length: results and complications. J Pediatr Orthop (2000) 1.64
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab (1999) 1.62
Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab (1998) 1.58
Pre- and postoperative intra-articular analgesia for arthroscopic surgery of the knee and arthroscopy-assisted anterior cruciate ligament reconstruction. A double-blind randomized, prospective study. Knee Surg Sports Traumatol Arthrosc (1997) 1.57
Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg (2001) 1.54
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (2010) 1.47
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) (2009) 1.46
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.46
Spinal deformity index in patients with type 2 diabetes. Endocrine (2012) 1.45
Deoxyhypusine hydroxylase from rat testis. Partial purification and characterization. J Biol Chem (1986) 1.44
The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004) 1.44
Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J (1997) 1.43
[Prevalence of inapropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes]. Rev Clin Esp (2012) 1.41
CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol (1995) 1.40
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) (2000) 1.40
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest (2009) 1.39
[Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus]. Minerva Med (1992) 1.39
ACROSTUDY: the Italian experience. Endocrine (2014) 1.38
Antiphospholipid antibodies cross-reacting with erythrocyte membranes. A case report. Clin Exp Rheumatol (1992) 1.38
Improved survival with screening for hepatocellular carcinoma. Liver Transpl (2000) 1.37
Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg (2002) 1.35
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer (2007) 1.33
Vertical gradient of regional lung inflation in adult respiratory distress syndrome. Am J Respir Crit Care Med (1994) 1.32
TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS (1994) 1.29
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis (2010) 1.29
Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology (1991) 1.29
Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages. Int J Med Microbiol (2000) 1.27
The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids (2001) 1.26
Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis. Clin Exp Immunol (1990) 1.26
Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) (1997) 1.25
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol (2009) 1.23
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol (2008) 1.23
Primary empty sella: Why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest (2010) 1.21
Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets (2005) 1.21
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer (2003) 1.21
Epidemiology of boutonneuse fever in western Sicily. Distribution and prevalence of spotted fever group rickettsial infection in dog ticks (Rhipicephalus sanguineus). Am J Epidemiol (1986) 1.21
Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging (2007) 1.20
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis (2011) 1.18
Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab (2006) 1.17
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab (1999) 1.17
The heart: an end-organ of GH action. Eur J Endocrinol (2004) 1.16
Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated patients with type 1 diabetes. Diabetes Technol Ther (2006) 1.16
Two-dimensional coronary MR angiography without breath holding. Radiology (1996) 1.15
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis (2011) 1.14
Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest (2008) 1.14
Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol (2008) 1.14
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol (2010) 1.14
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ (1999) 1.13
In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine (1995) 1.13
Percutaneous aspiration biopsy of the pancreas under ultrasonic guidance. N Engl J Med (1975) 1.12
Naloxone-reversible antinociception by paracetamol in the rat. J Pharmacol Exp Ther (1997) 1.11
The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol (1996) 1.10
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. Curr Drug Targets (2005) 1.10
Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod (2007) 1.10
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets (2009) 1.10
Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens (1999) 1.10
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol (2012) 1.09
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell Prolif (2012) 1.09
The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem (2003) 1.09
eIF5A isoforms and cancer: two brothers for two functions? Amino Acids (2011) 1.09
The role of the surgeon in the evolution of flexible endoscopy. Surg Endosc (2006) 1.09
WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep (2010) 1.09